# Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

> **NCT04094909** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 186 (estimated)

## Conditions studied

- Staging IV NSCLC

## Interventions

- **DRUG:** Rh-endostatin

## Key facts

- **NCT ID:** NCT04094909
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-06
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094909, "Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04094909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*